AHP,
Clearly we can't be specific as to what we'll earn from each batch of vaccine we make, but everyone believe the full course of treatment will be in somewhere in six figures. Once we have the FlaskWorks unit approved only a few hours of time by people who should be well paid, the point is, it still won't cost a great deal in labor. The units themselves were estimated to cost tens of thousands by others here, I suspect they're about right if mass produced. The disposable cassettes are primarily glass and plastic, specially handled and treated, but probably not a thousand each if mass produced. Certainly the facilities they're housed in or the cryogenic capability adds expense, but probably not more than a few thousand on a per batch basis.
I'm only suggesting that even if each batch of vaccine came to $25K, which I suspect is high, the profit would still be substantial with a six figure price. Many drugs that cost as much or more than DCVax-L may only cost dollars to make, but tens or hundreds of millions have been spent on the equipment making them, and of course all these drugs, including DCVax-L have cost hundreds of millions or more to develop, in that way there are similarities, as well as differences. The point is that with approval there will be plenty of money to be made with DCVax-L just as there is with any major drug. DCVax-L in GBM should become part of the SOC and it won't take long to become a blockbuster in GBM alone, it will be a blockbuster many time over if other solid cancers have benefits. I don't care if personalized products cost more to make, when they're blockbusters they'll be very profitable.
Gary
